Moderna’s Flu Vaccine Demonstrates Stronger Immune Response Against All Four Strains in Late-Stage Trial
On the 16th, Moderna announced a significant breakthrough in the development of its flu vaccine. The company revealed that its vaccine showcased a stronger immune response against all four strains of the flu virus compared to other flu vaccines in a late-stage trial. This groundbreaking news highlights Moderna’s commitment to revolutionizing the field of vaccination.
In addition to this remarkable achievement, Moderna also revealed its plans to curtail manufacturing of its highly successful COVID-19 vaccine. With the approval of US regulators, the company aims to reach its target gross profit increase of 75-80% at a faster pace due to reduced demand following the COVID-19 pandemic. This strategic decision not only ensures Moderna’s financial success but also allows the company to refocus its efforts towards other critical healthcare needs.
Modern CEO Stephen Hodge emphasized that the company is already engaging in discussions with partners to scale back production of its mRNA-based COVID-19 vaccine. After years of manufacturing billions of vaccine doses annually, Hodge believes that it is the right time to reorganize their facilities and adapt to emerging healthcare challenges.
Looking towards the future, Moderna aims to diversify its portfolio by introducing up to 15 new products over the next five years. By shifting their focus away from COVID-19 vaccines, the company demonstrates its long-term commitment to tackling various health threats and making a meaningful impact on public health.
Investors, while anticipating a drop in Moderna’s profits due to reduced production of the COVID-19 vaccine, are optimistic about the company’s new respiratory syncytial virus and flu vaccines. This move not only strengthens Moderna’s position in the vaccine market but also highlights their dedication to addressing the ongoing global health crisis.
The remarkable success showcased by Moderna’s flu vaccine is a testament to the groundbreaking research and innovation happening in the field of vaccination. As the company continues to forge ahead with its ambitious plans, it is clear that Moderna is poised to transform the landscape of preventive medicine.
Medical Today Reporter: Cho Min-gyu (awe0906@mdtoday.co.kr)
[Copyright ⓒ Medical Today. Unauthorized reproduction and redistribution prohibited]
▲ On the 16th (local time), Moderna announced that its flu vaccine produced a stronger immune response against all four strains of the flu virus compared to other flu vaccines in a late-stage trial. (Photo = DB)
[메디컬투데이=조민규 기자] Moderna announced on the 16th (local time) that its flu vaccine produced a stronger immune response against all four strains of the flu virus compared to other flu vaccines in a late-stage trial.
Moderna also announced it would curtail manufacturing of its COVID-19 vaccine.
It has been approved by US regulators and will allow the company to reach its target gross profit increase of 75-80% faster in response to reduced demand following the COVID-19 pandemic.
Moderna said it could launch up to 15 products over the next five years as it shifts its focus away from COVID-19 vaccines.
Moderna CEO Stephen Hodge said the company is in discussions with partners to scale back production of its mRNA-based COVID-19 vaccine. He also noted that the moment has come to reorganize manufacturing facilities after years of producing a billion doses of vaccine per year.
Investors are anticipating Moderna’s drop in profits due to reduced production of a COVID-19 vaccine being replaced by respiratory syncytial virus and flu vaccines.
Medical Today Reporter Cho Min-gyu (awe0906@mdtoday.co.kr)
[저작권자ⓒ 메디컬투데이. 무단전재-재배포 금지]
#Moderna #announces #flu #vaccine #trial #results #reduces #manufacturing #COVID19 #vaccine
